Nippon Kayaku Co., Ltd.
https://www.nipponkayaku.co.jp/english/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nippon Kayaku Co., Ltd.
Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Venture Funding Deals: Locana Gets Ready To Take On ALS, Huntington's With Gene Editing
The series A fundraising will help Locana bring CRISPR gene editing to diseases with dysfunctional RNA. Artizan and OncoMyx are among the other firms with recent series A rounds.
People Round-Up: Stada Brings In Consumer Expert To Lead German Business
Stada has turned to the FMCG world to find a head for its German operations, while former FDA commissioner Scott Gottlieb has linked up with Pfizer, and Nippon Kayaku has a new pharma head.
Asia Executives On The Move: BMS Names New China GM, New President For Nippon Kayaku
The coming of summer has seen a flurry of executive changes in the Asia Pacific biopharma sector. BMS has named a new China GM amid a fierce immuno-oncology battle, Parexel Japan has a new president, and other personnel changes take place at Nippon Kayaku, Zai Lab and Harbour BioMed.
Company Information
- Industry
- Biotechnology
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- Euro Nippon Kayaku GmbH